Corning and BioCision Form Global Distribution Agreement for Cell Cryopreservation Portfolio

We use cookies to ensure the best experience on our website.
View Cookie Policy
Accept Cookie Policy
Change My Settings
Required for the site to function.
Augment your site experience.
Lets Corning work with partners to enable social features and marketing messages.
Global Distribution Agreement for Cell Cryopreservation Portfolio

Global Distribution Agreement for Cell Cryopreservation Portfolio

Global Distribution Agreement

News Releases
Corporate Communications
Corning and BioCision Form Global Distribution Agreement for Cell Cryopreservation Portfolio
Corning and BioCision Form Global Distribution Agreement for Cell Cryopreservation Portfolio
Corning, N.Y. | Corning Life Sciences | November 12, 2015
Corning to become global channel distributor for select BioCision products

CORNING, N.Y., AND SAN RAFAEL, CALIF. – Corning Incorporated (NYSE: GLW) and BioCision, LLC today announced an agreement that will enable laboratories around the world to further standardize and simplify key steps in their cell culture workflow.

On January 1, 2016, Corning will become the global distributor of popular BioCision products, including the innovative CoolCell® cell cryopreservation systems, CoolBox™ ice-free sample preparation systems, CoolRack® systems, and other associated products.

BioCision’s technologies are designed to standardize temperature-sensitive areas of the cell culture workflow, making sample handling more consistent and experimental outcomes more reproducible. This agreement will expand the reach and availability of these products by utilizing Corning’s global sales team and worldwide distribution network.

“Corning prides itself on continuously looking for ways to improve and streamline the workflow for our cell culture customers,” said Keith R. Olson, PhD, Corning Cell Culture business director. “BioCision’s solutions improve sample handling, as well as provide eco-friendly alternatives to current methods. The addition of BioCision products is a perfect complement to our expanding cell culture portfolio of vessels, surfaces and media.”

“Corning is a preeminent life science research company that shares our commitment to deliver high quality research tools to our mutual customers,” said Rolf O. Ehrhardt, MD, PhD, BioCision chief executive officer. “This agreement provides unparalleled access to our workflow standardization solutions and also allows BioCision to focus on innovation in sample and drug product handling.”

The products covered in the Corning and BioCision agreement include:

  • CoolCell® alcohol-free cell freezing containers
  • CoolBox™ ice-free bench top cooling systems
  • CoolRack®, CoolSink®, and ThermalTray™ thermo-conductive sample tube and plate modules
  • TruCool® ice pans and buckets
  • CryoCeps™ cryogenic vial grippers

Corning Life Sciences continues to bring new and innovative laboratory technologies to researchers worldwide and help customers succeed by providing novel, high-quality products and services in cell culture, bioprocessing, drug discovery and development, genomics, and microbiology.

To learn more about Corning’s Life Sciences products, please contact a customer service representative at 1-800-492-1110, toll free in the United States; (+1) 1-978-442-2200 internationally; or visit

Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning’s financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the effect of global political, economic and business conditions; conditions in the financial and credit markets; currency fluctuations; tax rates; product demand and industry capacity; competition; reliance on a concentrated customer base; manufacturing efficiencies; cost reductions; availability of critical components and materials; new product commercialization; pricing fluctuations and changes in the mix of sales between premium and non-premium products; new plant start-up or restructuring costs; possible disruption in commercial activities due to terrorist activity, armed conflict, political or financial instability, natural disasters, adverse weather conditions, or major health concerns; adequacy of insurance; equity company activities; acquisition and divestiture activities; the level of excess or obsolete inventory; the rate of technology change; the ability to enforce patents; product and components performance issues; retention of key personnel; stock price fluctuations; and adverse litigation or regulatory developments. These and other risk factors are detailed in Corning’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.

Digital Media Disclosure
In accordance with guidance provided by the SEC regarding the use of company websites and social media channels to disclose material information, Corning Incorporated (“Corning”) wishes to notify investors, media, and other interested parties that it intends to use its website ( to publish important information about the company, including information that may be deemed material to investors. The list of websites and social media channels that the company uses may be updated on Corning’s media and website from time to time. Corning encourages investors, media, and other interested parties to review the information Corning may publish through its website and social media channels as described above, in addition to the company’s SEC filings, press releases, conference calls, and webcasts.

About BioCision
BioCision is a life science research and development company that standardizes processes from lab to patient. BioCision’s award-winning products enable researchers, clinicians and manufacturers to protect temperature sensitive therapeutics, biological samples, and biomaterials. By addressing temperature standardization, BioCision strives to improve the success of basic research, therapeutic discovery and development and enable effective care delivery.

For more information visit, or visit the BioCision blog for news and expert insight at

About Corning Incorporated
Corning ( is one of the world’s leading innovators in materials science. For more than 160 years, Corning has applied its unparalleled expertise in specialty glass, ceramics, and optical physics to develop products that have created new industries and transformed people’s lives. Corning succeeds through sustained investment in R&D, a unique combination of material and process innovation, and close collaboration with customers to solve tough technology challenges. Corning’s businesses and markets are constantly evolving. Today, Corning’s products enable diverse industries such as consumer electronics, telecommunications, transportation, and life sciences. They include damage-resistant cover glass for smartphones and tablets; precision glass for advanced displays; optical fiber, wireless technologies, and connectivity solutions for high-speed communications networks; trusted products that accelerate drug discovery and manufacturing; and emissions-control products for cars, trucks, and off-road vehicles.